Cytokine Release Syndrome
📧 Sign up to get email alerts when something new happens for Cytokine Release Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
EMA authorised Tuyory from Chemical Works of Gedeon Richter Plc. for multiple indications including rheumatoid arthritis, juvenile arthritis…
-
EMA approval · 2026-08-19EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
Tyenne (tocilizumab) has been authorised by the EMA for multiple indications including rheumatoid arthritis, cytokine release syndrome, juve…
-
EMA approval · 2026-08-13EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juveni…
-
EMA approval · 2026-06-15EMA Authorised: Tuyory — Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.)
Tuyory has been authorised by the EMA for multiple indications including rheumatoid arthritis, juvenile arthritis, cytokine release syndrome…
-
EMA approval · 2026-06-09EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
Avtozma (tocilizumab) has been authorised in the EU for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-01EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH
EMA authorised RoActemra (tocilizumab) for multiple indications, including rheumatoid arthritis, juvenile idiopathic arthritis, cytokine rel…
-
EMA approval · 2026-01-26EMA Authorised: Avtozma (tocilizumab) — Celltrion Healthcare Hungary Kft.
EMA has authorized Avtozma, a tocilizumab biosimilar, for rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome, an…
-
FDA approval · 2026-01-14FDA Approved: AVTOZMA — Supplemental Application (CELLTRION USA, Inc.)
FDA approves a supplemental application for AVTOZMA (tocilizumab) filed by Celltrion USA, Inc.
-
FDA approval · 2025-12-10FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc.
-
EMA approval · 2025-10-02EMA Authorised: Tyenne (tocilizumab) — Fresenius Kabi Deutschland GmbH
EMA authorised Tyenne (tocilizumab) by Fresenius Kabi Deutschland GmbH for multiple indications, including rheumatoid arthritis, juvenile id…
-
FDA approval · 2025-05-12FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-03-13FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for TYENNE (tocilizumab-AAZG) from Fresenius Kabi USA, LLC.
-
FDA approval · 2021-10-22FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) from Genentech, expanding its labeling and/or indications. The action conf…
-
FDA approval · 2017-05-22FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. The supplementary filing status is AP (approv…
-
FDA approval · 2014-11-13FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for ACTEMRA (tocilizumab) submitted by Genentech, Inc. This action involves an approved product …
-
FDA approval · 2012-08-13FDA Approved: ACTEMRA — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Actemra (tocilizumab) submitted by Genentech, broadening its labeling.